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Abstract
Background: Identifying disease gene from a list of candidate genes is an important task in
bioinformatics. The main strategy is to prioritize candidate genes based on their similarity to known
disease genes. Most of existing gene prioritization methods access only one genomic data source,
which is noisy and incomplete. Thus, there is a need for the integration of multiple data sources
containing different information.
Results: In this paper, we proposed a combination strategy, called discounted rating system
(DRS). We performed leave one out cross validation to compare it with N-dimensional order
statistics (NDOS) used in Endeavour. Results showed that the AUC (Area Under the Curve) values
achieved by DRS were comparable with NDOS on most of the disease families. But DRS worked
much faster than NDOS, especially when the number of data sources increases. When there are
100 candidate genes and 20 data sources, DRS works more than 180 times faster than NDOS. In
the framework of DRS, we give different weights for different data sources. The weighted DRS
achieved significantly higher AUC values than NDOS.
Conclusion: The proposed DRS algorithm is a powerful and effective framework for candidate
gene prioritization. If weights of different data sources are proper given, the DRS algorithm will
perform better.
Background
Genes related to causing some diseases are called
disease-causing genes or disease genes. A pertinent role
for bioinformatics research exists in the analysis of
biological data for disease gene discovery. Most current
efforts at disease-gene identification involving linkage
analysis and association studies result in a genomic
interval of 0.5-10 centi Morgen containing up to 300
genes [1,2]. These candidate genes need to be further
investigated to identify disease causing genes. But
identifying the real disease genes from the large amount
of candidate genes by biological experiment is time
consuming and labor-extensive. To address the chal-
lenge, computational prediction of good candidate genes
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Open Accessbefore experimental analysis is quite necessary, which
will save both time and effort. The main strategy is to
prioritize candidate genes by their similarity to known
disease genes, which is called candidate gene prioritiza-
tion.
With the advent of high-throughput technologies, huge
amount of genomic data have been generated. There-
fore, there are many ways to define ‘functional
similarity’ between genes. A number of methods have
been proposed to prioritize candidate genes based on
different kinds of genomic data, such as sequence-based
features [3-5], functional annotation data [6,7] and
protein interaction data [8,9]. However, most of these
data sources are noisy and incomplete, which down-
grades the prioritization algorithms. How to effectively
integrate heterogeneous data sources to improve pre-
diction is a major challenge. Notably, there are two
combination algorithms. On is Endeavour, proposed by
Aerts et al. [10]. They integrated nine data sources, e.g.
sequence data, gene annotation data, etc. There are two
stages in the framework of Endeavour. In the first stage,
a rank list of candidate genes is calculated according to
their similarity to known disease genes based on each
data source. In the subsequent stage, these rank lists
were integrated into one rank list using N-dimensional
order statistics (NDOS) [11]. Another combination
algorithm is multiple kernels learning (MKL), proposed
by De Bie et al. [12]. For each data source, a kernel
matrix was used to measure the similarity between
genes. They used one-class SVM trained on the
combined kernel to prioritize candidate genes. They
compared MKL with Endeavour on 29 diseases, and
found that MKL works better than Endeavour. In our
previous work, we improved the first stage of Endea-
vour, the ranking algorithm, and achieved higher AUC
values than MKL [13]. In this paper, we combined
Protein Protein Interaction (PPI) data and Gene
Ontology (GO) data to prioritize candidate genes. We
follow the framework of Endeavour and did improve-
ments on both stages, the ranking algorithm and the
combination algorithm.
Rank lists of candidate genes were obtained using
random walk with restart (RWR) algorithm [9]. Firstly,
each data source is transformed into a network (graph).
Protein-protein interaction data is directly transformed
into a network as the node and edge information are
available. Three K-nearest neighbor (KNN) graph were
derived from gene ontology annotation, corresponding
to three sub-ontologies, ‘biological process’, ‘cellular
components’ and ‘molecular function’. We found the
sub-ontology ‘biological process’ was the most effective
in prioritizing candidate genes among four data source
used.
To combine these rank lists, we proposed a new
algorithm, called discounted rating system (DRS). It is
inspired by Discounted Cumulated Gain (DCG) score,
which is widely used to evaluate the ranking results of
document retrieval [14]. Similar to NDOS, our algorithm
starts from several rank lists of candidate genes. The rank
l i s t sa r et r a n s f o r m e di n t od i s c o u n t e dr a t i n gl i s t st h r o u g h
the discounted rating system. Then, candidate genes are
ranked based on the mean value of discounted rating
scores corresponding to each data source. The perfor-
mance is evaluated by area under ROC curve (AUC)
value using leave one out cross validation. In compar-
ison with NDOS, DRS achieved comparable AUC values
for most of the disease families. But DRS works much
faster than NDOS, especially when there are a large
number of data sources. When there are 100 candidate
genes and 20 data sources, DRS works more than 180
times faster than NDOS. In addition, we propose to give
different weights for different data sources. The AUC
values for the weighted DRS were statistically significant
higher than NDOS.
The rest of this paper is organized as follows. We begin
with the description of the data sets used in this work,
and then introduce the related algorithms and our
proposed DRS. We evaluate its performance on 36
disease families and compare it with NDOS. The last
section concludes the paper with a brief summary.
Methods
In this section, we firstly introduce the data used in this
work: disease genes, protein-protein interaction (PPI)
data and gene ontology (GO) [15]. Then, we introduce
the ranking algorithm based on random walk and the
combination algorithm N-dimensional order statistics
(NDOS) used in Endeavour [10]. Finally, we describe
our newly proposed combination algorithm discounted
rating system (DRS).
Disease genes
D i s e a s eg e n ed a t as e tw a sc o l l e c t e db y[ 9 ] ,w h i c hw a s
defined on the basis of entries in the Online Mendelian
Inheritance in Man (OMIM) database [16]. There were
110 disease gene families; the largest family contained
47 genes and the smallest only three genes. In this work,
we choose 36 disease families, each of which includes at
least 6 genes. These disease families include genetically
heterogeneous disorders in which mutations in distinct
genes are associated with similar or even indistinguish-
able phenotypes; cancer syndromes comprising genes
associated with hereditary cancer, increased risk, or
somatic mutation in a given cancer type; and complex
(polygenic) disorders known to be influenced by
variation in multiple genes.
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The PPI data were derived from Human Protein Reference
Database (HPRD) [17] and BioGRID [18]. HPRD
contains manually curated scientific information pertain-
ing to the biology of most human proteins. All the
interactions in HPRD are extracted manually from
literatures by expert biologists who read, interpret and
analyze the published data. The BioGRID is also a curated
database for protein-protein interaction. It is compiled by
in-house large scale curation efforts. It contains both
physical interaction data and genetic interaction data. In
total, there are 40,578 unique interactions between 9,689
proteins in these two databases. The interaction data can
be used to construct a network, in which nodes are
proteins and edges are interactions.
Gene Ontology and gene functional similarity network
Gene Ontology
The Gene Ontology (GO) provides a controlled vocabu-
lary to describe gene and gene product attributes [15]. It
is comprised of three independent sub-ontologies,
‘biological process’ (BP), ‘cellular component’ (CC)
and ‘molecular function’ ( M F ) .B Pr e f e r st oab i o l o g i c a l
objective to which the gene or gene product contributes.
It often involves a chemical or physical transformation.
Examples of general (high level) biological process terms
are ‘metabolism’ or ‘signal transduction’.E x a m p l e so f
more specific (lower level) process terms are ‘pyrimidine
metabolism’ and ‘cAMP biosynthesis’. CC refers to the
place in the cell where a gene product is active. It
includes terms such as ‘nuclear membrane’ or ‘Golgi
apparatus’. MF is defined as the biochemical activity
(including specific binding to ligands or structures) of a
gene product. This definition also applies to the
capability that a gene product (or gene product complex)
carries as a potential. It describes only what is done
without specifying where or when the event actually
occurs. Examples of broad functional terms are ‘enzyme’,
‘transporter’ or ‘ligand’. Examples of narrower functional
terms are ‘adenylate cyclase’ or ‘Toll receptor ligand’.
The functional similarity between two genes can be
measured by the semantic similarity between their GO
annotation terms [19-22]. Since there are three indepen-
dent sub-ontologies, the functional similarity can be
defined considering three different aspects. Therefore, we
constructed three gene similarity networks, according to
three sub-ontologies. In this work, the similarity between
two genes is measured by their overlap annotation terms
[22], because of its computational efficiency.
Gene functional similarity network
Before constructing KNN graphs, a gene-term annotation
matrix was compiled for the corresponding sub-
ontology. Each column in the matrix represents the
annotation vector of a gene. The annotation vector is
binary valued, with ‘1’ representing the presence of the
GO term in the gene’sa n n o t a t i o na n d‘0’ representing its
absence. The functional similarity between two genes can
be calculated by the dot product between the corre-
sponding annotation vectors, which is the number of co-
annotated terms. Intuitively, genes sharing specific term
‘pyrimidine metabolism’ are expected to be more
functionally similar than genes sharing general term
‘metabolism’. Therefore, the ‘1’ values in the annotation
vector are replaced by the information content (IC) of
the corresponding GO term. The information content of
a term is related to how often the term is associated to
genes in the database, such that rarely used terms are
assigned with higher IC. The calculation of IC is
described as follows:
IC log n n tt =− (/ ) (1)
where n is the total number of genes in the sub-ontology
and nt is the number of genes annotated with term t.
The functional similarity between two genes are calcu-
lated by dot product between corresponding weighted
annotation vectors
kg g x x ij i
T
j (,) = (2)
where gi and gj are gene i and gene j,a n dxi and xj are the
corresponding annotation vectors, weighted by IC
values.
For each gene, we calculate the functional similarity
between this gene and any other gene in the sub-
ontology using Eq.(2), and find K most similar genes of
it, called K-nearest neighbors. Then the gene is connected
with its K-nearest neighbors, weighted by the similarity
measure calculated by Eq.(2). The network (graph)
constructed by this method is called the K-nearest
neighbor (KNN) graph. In this work we use 5-NN graph.
Ranking algorithm based on random walk with restart
Let G(V, E) be a graph, where V is the set of nodes and E
is the set of edges. Random walk [23] method simulates
a random walker that starts on a source node (or a set of
source nodes simultaneously). At each step, the walker
chooses randomly among its immediate neighbors
(based on edge weights). The transition probability
from node i to node j is
MA d i ij ij = /( ) (3)
where A is the adjacency matrix of the graph, d(i)i st h e
sum of the ith column in A. The transition matrix M of
BMC Bioinformatics 2010, 11(Suppl 1):S20 http://www.biomedcentral.com/1471-2105/11/S1/S20
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as
MDA =
−1 (4)
where D is the diagonal matrix of the degrees (∀i, Dii =
d(i)a n dDij =0f o ri = j).
Let ps be a vector in which the ith element holds the
probability of finding the random walker at node i at
step s. The probability at step s +1c a nb eg i v e nb y
pM p s
T
s + = 1 (5)
The initial probability vector p0 is constructed such that
equal probabilities are assigned to all the source nodes
with the sum of the probabilities equal to 1. This is
equivalent to letting the random walker begin from each
of the source nodes with equal probability.
Random walk with restart (RWR) is a variant of the
random walk. At each step, the random walker moves to
its immediate neighbor or goes back to source nodes
with probability g. Formally, the random walk with
restart is defined as:
pM p p s
T
s + =− + 10 1 () γγ (6)
After certain steps, the probability will reach a steady
state. This was obtained by performing the iteration until
the difference between ps and ps+1 (measured by the L1
norm) fell below 10
-10. The steady state probability p∞
gives a measure of proximity to source nodes. If p∞ (i)
>p∞ (j), then node i is more proximate to source nodes
than node j. RWR algorithm has been used on PPI
network to prioritize candidate genes, with nodes
representing known disease genes as source nodes. The
hypothesis is that disease genes of a particular disease are
located in same ‘modules’ [9].
N-dimensional order statistics used in Endeavour
N-dimensional order statistics (NDOS) used as compar-
ison in this paper was proposed by [11]. It has been used
in Endeavour to combine multiple data source and
prioritize disease genes [10]. Before using NDOS, they
generate a rank list for candidate genes based on each
individual data source. Therefore, each candidate gene
yields N rank positions r1, r2,. . . ,rN,w h e r eN is the
number of data sources used. Then, N ranking positions
from the separate data sources are combined into a Q
value using NDOS, which is calculated by the following
recursive formula:
Qr r r N r r Qr r r r NN i N iN i N i ( , ,..., ) ! ( ) ( , ,..., , ,... 12 1 12 2 =− −+ − − −+ , ,) rN
i
N
= ∑
1
(7)
with r0 = 0. Finally, all the genes are ranked by
corresponding Q values. Thereafter, the combined rank
list was derived from the separate rank list. The
computational complexity is O(N!), and Endeavour
[10] implemented a faster alternative formula with
complexity O(N
2).
Discounted rating system
Similar to Endeavour, in the begining, we obtain a rank
list for the candidate genes based on each individual data
source. Here, we propose a new strategy, discounted
rating system (DRS) to combine these rank lists into one.
Figure 1(a) shows the input of DRS, rank list of 100
candidate genes obtained by using RWR based on each
individual data source. And the output of DRS is shown
in Figure 1(e). Four steps of DRS are described below.
Figure 1
Illustration of discounted rating system. This figure shows four steps of DRS. SN is the serial number of candidate gene.
Firstly, rank lists are transformed into rating lists. Secondly, discounted rating scores are calculated. In the next step,
combined scores are calculated. Finally candidate genes are ranked using the combined score.
BMC Bioinformatics 2010, 11(Suppl 1):S20 http://www.biomedcentral.com/1471-2105/11/S1/S20
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Candidate genes are categorized into five equal-size
ratings based on their rank positions in the rank list.
The higher the rating, the more relevant is the gene to
the disease.
2) In the second step, the rating and ranking of each
gene is combined into one value called discounted
rating (dr). The discounted rating of a gene based on
data source i is calculated as follows:
dr
rattingi
log ri
i =
+ 2 1 ()
(8)
where ratingi isthe rating of the investigated candidate
gene based on data source i and ri is its rank position.
The discounting function log2(ri + 1) reduces the
gene’s rating as its rank increases. The calculation of
discounted ratings is inspired by DCG (Discounted
Cumulated Gain) score, which is widely used to
evaluate the ranking results of document retrieval
[14]. The higher position ranks have more influence
than the lower position ranks. Our assumption is that
disease genes are ranked somewhere in the top of the
rank lists according to some data sources.
3) In the next step, the mean value of discounted
ratings is calculated as the combined score for the
investigated gene.
S
N
dr dr i
i
N
=
= ∑
1
1
(9)
where N is the number of data sources used.
4) Finally, the candidate genes are ranked according
to this score.
Considering 100 candidate genes, the whole procedure
of DRS is illustrated in Figure 1. For example, the rank
positions of the 8th gene, g8,o b t a i n e db yR W Rb a s e do n
BP, CC, MF and PPI, is given by 4, 2, 13 and 3,
respectively. That is, for g8, r1 =4 ,r2 =2 ,r3 =1 3a n d
r4 = 3. After transformed into ratings, they are all 5. In
the next step, their dr values are 2.15, 3.15, 1.31, and 2.5,
respectively. The combined score for g8 is 2.28. Finally,
each candidate gene has a combined score, based on
which, all the candidate genes are ranked as the
combined rank list. The most likely real disease is g8,
because it is finally ranked 1st. In the combined rank list,
g3 and g100 are ranked 2nd and 3rd, they may also be real
disease genes.
Weighted discounted rating system
Discounted rating system can be thought as a kind of
ensemble strategy. Different data source should be given
different weights in the decision of the combined
ranking, since different data sources differ in their
usefulness and suitability to rank candidate genes for a
certain disease family. The weighted DRS (WDRS) is
calculated as follows:
S i dri i
N
i i
N wdr =
∗ = ∑
= ∑
() μ
μ
1
1
(10)
where μi is the weight for data source i.I nt h i sw o r k ,
weights are obtained by using cross validation as
described in the next section.
Cross validation
To assess the performance of these prioritization
methods, we use leave one out strategy proposed in
[10], which is illustrated in Figure 2. Firstly, for each
disease gene, we retrieve the 99 nearest genes form the
up-stream and down-stream genetic interval of the
disease gene. For the investigated disease family, in
each validation run, we hold out one gene from the set
of disease genes. The held-out gene and 99 genes are
called test set. And the remaining disease genes for the
investigated disease family are called training set and
used as source nodes of random walk algorithm to
prioritize test genes. Ideally, the held-out gene should be
on the top of the test genes’ rank list.
Therefore, for each disease gene, we obtain a rank list of
test genes, that is, prioritizations of 100 genes. Suppose
there are 8 disease genes in the investigated disease
family, after cross validation, we obtain 8 rank lists, each
with 100 prioritizations. Then, from these 800 prior-
itizations, we calculate sensitivity and specificity values
of the investigated disease family at varying thresholds.
Sensitivity refers to the percentage of disease genes that
Figure 2
The procedure of leave one out cross validation.F o r
the investigated disease family, one disease gene and 99
nearest genes form the test set. The other disease genes are
training genes, used as source nodes of RWR (random walk
with restart) algorithm. Test genes are ranked by the RWR
algorithm. Ideally, the held-out gene should be ranked top.
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refers to the percentage of non-disease genes ranked
below this threshold. For instance, a sensitivity/specifi-
city value of 70/90 would indicate that the correct
disease gene is ranked among the best-scoring 10% of
genes in 70% of the prioritizations. We plot receiver
operating characteristic (ROC) curves and use the area
under this curve (AUC) as a standard measure of the
performance. For instance, an AUC value of 100%
indicates that every held-out gene is ranked first.
Results and discussion
In this section, we first compared NDOS and DRS in
detail, taking Esophageal Carcinoma as an example.
Then, the performance of NDOS and DRS on all 36
disease families was compared. After that, we investi-
gated the effect of parameter g in RWR. Finally, we
compared NDOS and DRS on larger number of
simulated data sources.
Case study of Esophageal Carcinoma
Esophageal Carcinoma is a kind of cancer, which have a
high incidence in China, India, Japan and United
Kingdom. There were 10 disease genes for the disease
of Esophageal Carcinoma [9]. We used the leave one out
cross validation to evaluate the performance of our
algorithm. In each validation run, one known disease
gene and 99 nearest genes were treated as test set. The
rest known disease genes of Esophageal Carcinoma were
t r e a t e da st r a i n i n gs e ta n du s e da ss o u r c en o d e sf o rR W R
algorithm.
The rank position of the held-out disease gene is shown
in Table 1. Since most of the data sources are
incomplete, some genes may not be included in all the
data sources. NDOS and DRS solve this problem by
adjusting N in Eq. 7 and Eq. 9, respectively. As can be
seen from Table 1, for most of the disease genes, the
ranks of both methods are comparable. The ranks of
DEC1 and DLEC1 by DRS is better than NDOS, because
they were ranked near to the top by at least one data
source and in DRS the combined ranks were dominated
by top rank positions. The last row in the table shows
the AUC scores corresponding to the data sources or
combination algorithms. For each data source, the AUC
value is calculated on available disease genes in this data
source. In the case of Esophageal Carcinoma, the AUC
value of DRS (90.4%) is higher than that of NDOS
(87.4%).
As can be seen from Table 1, for different data source, the
predictive ability is different. Therefore, when calculating
the combined score for candidate genes, we gave weight
for each data source based on its AUC value.
μii max auc =− (, .) 00 7 (11)
where auci is the AUC value corresponding to data source
i.T h e n ,μi was plunged into Eq.(10) to calculate Swdr the
combined score of weighted DRS. More effective data
sources were given higher weights and were able to play
more important role in the decision of the combined
score Swdr, and thereafter the gene’s rank position. The
data sources with AUC below 0.7 are filtered out, since
the weight of which are set zero. We choose 0.7 to ensure
the predictive data sources are highlighted and not to
filter out much data sources. In the case of Esophageal
Carcinoma, the data source of PPI and BP dominate the
final ranks of disease genes.
Performance on all 36 disease families
We applied DRS on 36 disease families. AUC values of
the leave one out cross validation for each disease family
are shown in Table 2. For most of the disease families,
the AUC values for DRS and NDOS are comparable. And
the AUC values for WDRS are higher than DRS and
NDOS. To make it more clear, we performed Wilcoxon
signed-rank test between AUC values of WDRS and
NDOS, and found that WDRS was significantly better
than NDOS (p =1 . 5 1×1 0
-2). Similarly, the permeance
of weighted DRS was much better than non-weighted
version (p =1 . 3 4×1 0
-6).
There are 497 disease genes in all the 36 disease families.
As shown in Figure 2, for each disease gene, we obtained
a rank list of 100 test genes. We put all 497 rank lists
together and constructed a ROC curve, which is shown in
the left panel of Figure 3. It is clear that the ROC curve
for WDRS is above DRS and WDRS, therefore the AUC
value of WDRS is larger than DRS and NDOS.
As described in the section of cross validation, the
sensitivity value at 1 - Specificity = 10% means the
proportion of real disease genes in the top 10% ranked
genes of 497 rank lists. The right panel is the zoom-in
ROC plot of top 10% candidate genes. The DRS
Table 1: Results of Esophageal Carcinoma
Gene Name PPI BP CC MF NDOS DRS WDRS
T P 5 3 24151 1 3
C D K N 2 A 43191 2 5
D E C 1 -2--1 7 21
DCC 11 3 55 22 15 15 12
DLEC1 - 1 27 - 10 1 1
TGFBR2 20 34 60 32 44 48 40
A P C 723 7 72 5 4
L Z T S 1 593 2 53 8 5
W W O X 132 6 1 8 2 3 2
R N F 6 ---1 5 4 1 2 1 2 2
AUC value (%) 93.9 94.2 71.1 86.9 87.4 90.4 91.5
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SN Disease Family No. of Disease Genes AUC Value(%)
DRS WDRS NDOS
1 Amyotrophic lateral sclerosis 8 87.5 87.3 90.0
2 Age-Related Macular Degeneration 12 79.7 80.2 79.8
3 Bardet-Biedly Syndrome 13 86.5 87.2 84.5
4 Breast Cancer 15 89.0 89.9 91.5
5 Chondrodysplasia punctata 14 98.6 99.1 98.6
6 Noonan Syndrome, Costello syndrome, Cardiofaciocutaneous Syndrome 9 97.6 97.9 99.0
7 Hypertrophic cardiomyopathy 15 84.1 84.0 84.0
8 Congenital myasthenic syndromes 10 99.9 99.9 99.8
9 Charcot Marie Tooth Disease 24 85.2 86.1 85.8
10 Cataract 11 83.8 84.0 83.0
11 Dilated cardiomyopathy 20 93.3 93.9 93.1
12 Epidermolysis bullosa 16 99.5 99.6 99.4
13 Ehlers Danlos syndrome 8 97.3 97.4 97.6
14 Esophageal carcinoma 10 90.4 91.5 87.4
15 Essential hypertension 12 87.2 89.3 85.0
16 Fanconi anemia 12 99.5 99.6 98.8
17 Glioma of brain 21 86.6 86.5 87.1
18 Hereditary nonpolyposis colorectal cancer 7 96.7 96.9 96.1
19 Hermansky-Pudlak syndrome 8 99.5 99.6 99.1
20 Inflammatory Bowel Disease 8 85.4 87.9 87.6
21 Leber congenital amaurosis 9 88.0 96.9 86.1
22 Limb-Girdle Muscle Dystrophy 14 96.1 96.8 94.9
23 Long QT Syndrome 9 95.9 96.3 95.7
24 Leigh Syndrome 24 72.8 73.4 73.2
25 Microphthalmia 9 83.4 85.1 87.3
26 Mitochondrial complex I deficiency disorders 16 84.1 84.0 84.1
27 Maturity-Onset Diabetes of the Young 19 82.7 85.6 82.6
28 Nonsyndromic hearing loss 47 95.8 96.5 94.7
29 Obesity 13 96.9 97.2 98.3
30 Parkinson 8 94.4 95.0 97.6
31 Pheochromocytoma 10 78.3 80.7 82.2
32 Retinitis Pigmentosa 23 96.4 98.7 95.1
33 Spinocerebellar Ataxia 13 73.2 75.6 73.7
34 Thyroid carcinoma 8 75.5 80.4 78.8
35 Xeroderma Pigmentosum 8 99.8 99.8 99.9
36 Prostate Cancer 14 80.8 84.7 81.9
Figure 3
ROC Curve corresponding to all the disease genes. The left panel shows the ROC curves of three combination
algorithms. The right panel is the zoom-in ROC plot of top 10% candidate genes.
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10% ranked genes of 497 rank lists. In the wet-lab
experiments, biologists pay more attention to the top
ranked genes. The DRS algorithm gives better guidance
for wet-lab experiments than NDOS. And the weighted
DRS performs even better.
The performance of individual data source were calcu-
lated based on the disease genes available in this data
sources. As shown in Table 3, among four data sources,
BP ontology achieved the highest AUC value (92.8%),
which was higher than the result of combined algo-
rithms. But 37 of the 497 disease genes can not be
prioritized by BP data source. The coverage of PPI
network was even smaller, 98 of 497 disease genes were
absent in the PPI network. As described in the section of
cross validation, 497 sets of test genes were retrieved
from the corresponding artificial linkage. For a data
source, a large number of genes were absent. The median
numbers of test genes are shown in Table 3.
Ranking algorithm based on individual data set can not
prioritize genes not presented in the data source, while
the combined algorithm can increase the scope of
application. If one gene is listed in any data source, it
can be prioritized.
The numbers of ratings
In the second step of DRS, we classify candidate genes
into 5 ratings. To investigate whether or not the number
of ratings has effect on the performance of DRS, we set
the number of ratings at 2 and 10 and calculated the
AUC values of leave one out cross validation. As can be
seen from Table 4, the scale of rating did not effect the
results significantly.
Stable performance of RWR algorithm
In the base ranker, RWR algorithm, there is one
parameter, the restart probability g . To investigate the
effect of this parameter, we set g at 0.6, 0.7, 0.8 and 0.9,
and did leave one out cross validation for both NDOS
and DRS. We calculated AUC value for each disease
family, and performed pair-wise t-test between two lists
of AUC values, as we did in the previous section. Results
a r es h o w ni nT a b l e5 .F o re a c hg value, performance of
DRS was significantly better than NDOS. We also
calculated the overall AUC values based on all the 497
disease genes. For both NDOS and DRS, the AUC values
did not change much with g value changing.
Comparison of NDOS and DRS with the
number of data sources increasing
In this work, there were 100 candidate genes and 4 data
sources. On a desktop with a 2.4 GHz Intel processor
and 1 GB RAM, the computational time of cross
validation using DRS and NDOS were found to be
0.18s and 9.4s, respectively. Both DRS and NDOS were
implemented in Matlab.
In the latest version of Endeavour [24], there are 20 data
sources available for H. sapiens.W et r i e dt oc o m p a r et h e
performance of NDOS and DRS, with the number of
data sources increasing. We did not add more real data
sources, but simulated the data as described subse-
quently. For the real data source, in each run of cross
validation, one known disease gene and 99 genes in the
nearest genetic interval are test genes, and a rank list of
these test genes is generated using RWR, as shown in
Figure 1(a). For the newly added data source, we
simulate the prioritization result of 100 test genes. We
suppose there are m test genes available in data new
source, m is chosen from the last column of Table 3. We
randomly select m genes from the 100 test genes. The
prioritization result of selected test genes is simulated as
a random permutation of integers from 1 to m.T om a k e
the simulation more reliable, the rank position of known
disease gene was randomly selected from distribution of
ranking positions of 497 known disease genes based on
real data source. In brief, for each known disease genes, 4
real rank lists were calculated and several simulated rank
lists were generated. Then, simulated rank lists and four
Table 3: Performance of individual data source
Data Source AUC
values (%)
No. of missing
disease genes
No. of available
test genes
BP 92.8 37 66
CC 85.4 59 59
MF 87.0 81 57
PPI 89.8 98 57
Table 4: Levels of ratings and AUC values
Ratings AUC Value(%)
DRS WDRS
2 89.2 90.2
5 89.3 90.4
10 89.4 90.5
Table 5: Stable performance of RWR with variation of g
AUC Value(%)
g NDOS DRS
0.6 89.4 89.2
0.7 89.4 89.3
0.8 89.5 89.4
0.9 89.4 89.4
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NDOS algorithm respectively, as shown in Figure 2, and
the corresponding combined rank list was generated.
Finally, 497 combined rankings were generated, based
on which AUC value was calculated.
As shown in Table 6, when the number of data sources
increasing, the computational time for NDOS was
dramatically increased, while it for DRS did not change
much. When the number of data sources increased to 20,
DRS was more than 180 times faster than NDOS used in
Endeavour. Since there are a large number of missing
values in the real data sources and simulated data
sources, the N value in Eq. 7 is much smaller than the
number of data sources and compute much faster than
complete data. But the incompleteness of the data have
little effect on the computation time on DRS. If there are
no missing values in the 20 data sources, the computa-
tion time of NDOS is around 300s.T h e r e f o r e ,D R S
performs more than 700 times faster than NDOS. With
the complexness of genomic data, the merit of DRS will
become more significant. On the other hand, for both
NDOS and DRS, the AUC value increased when the
number of data sources increasing. When the number of
data source came to 16, DRS achieved higher overall
AUC value than NDOS.
Conclusion
In this work, we integrated gene ontology data and PPI
data to prioritize candidate genes. The PPI data were
presented by the PPI network, and then random walk
with restart (RWR) algorithm was directly used on the
network. For gene ontology data, three KNN graphs were
generated corresponding to three sub-ontologies, BP, CC
and MF and RWR algorithm was used on the graphs to
prioritize candidate genes. Results showed that, BP
ontology was the most informative data source for
candidate genes prioritization. Due to the incomplete-
ness of each individual data source, some genes can not
be prioritized, while the combined method can make use
of all the data available.
We proposed a new strategy called discounted rating
system (DRS) to combine the rank lists of candidate
genes obtained by using RWR algorithm. In comparison
with NDOS [11] algorithm used in Endeavor [10], DRS
performed much faster and achieved higher AUC values
on most of the disease families. Another merit of DRS
algorithm is flexibility to give weights for different data
source. Especially, when the number of data sources
increases to 20, DRS works more than 180 times faster
than NDOS. The framework of DRS is flexible to give
weights on different data sources. Given proper weights
the DRS will works better. Results of leave one out cross
validation showed that weighted DRS achieved higher
AUC values than NDOS and non-weighted DRS.
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